Polaris Pharmaceuticals, Inc
4941 Allison Parkway, Suite B
About Polaris Pharmaceuticals, Inc
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. Our lead drug candidate, Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is involved in every stage of the drug development process. Our family of companies harnesses structure-based drug design technology to create novel oncology therapies, conducts clinical studies at top-tier cancer centers worldwide and operates cGMP Production Facilities in Northern California and China
Stock Exchange: Taiwan
Stock Symbol: 6550.TDW
6 articles with Polaris Pharmaceuticals, Inc
Polaris Pharmaceuticals, Inc. Vacaville has purchased 15 acres in the City of Vacaville’s Vaca Valley Business Park, a transaction that represents another advancement in the City’s plans to expand its biotechnology footprint and solidify itself as a global center for biomanufacturing.
Incidence rates for liver cancer began rising in the mid-1970s, and they are expected to go up through at least 2030. This report aims to give an overview of liver cancer, as well as explore current therapies, drugs in the pipeline and the future treatment landscape for patients and their caregiv...
Polaris Pharmaceuticals, Inc. announced that James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. have joined its Scientific Advisory Board.
Polaris Signs Collaboration Agreement with MD Anderson Cancer Center to Join its Immunotherapy Platform for Clinical Trials and Preclinical Research
Polaris Group announced that it has signed a multiyear strategic Collaboration Agreement with MD Anderson Cancer Center to utilize its Immunotherapy Platform, led by world-renowned immunotherapy pioneer Dr. James Allison, Dr. Padmanee Sharma, and Dr. Patrick Hwu, to design clinical studies and monitor biomarkers in immune functions associated with the therapies.
Polaris Pharmaceuticals Release: ADI-PEG 20 Is A Potential Salvage Therapy For BRAFi Resistant Melanoma